List view / Grid view
The International Federation of Pharmaceutical Manufacturers and Associations has announced that the biopharma industry has responding swiftly to the COVID-19 pandemic and will further increase its efforts.
As the world rushes to identify the best coronavirus treatments and vaccines, John Cahill rounds up the latest developments in potential COVID-19 therapies.
A clinical trial has shown that delivery of vaccines via a new high-density microarray patch (HD-MAP) induces a better immune response than needles or syringes.
Developers have announced that they are ready to manufacture and formulate an innovative novel coronavirus vaccine capsule.
The European Commision (EC) has announced €80 million of support to aid in the R&D and production of a COVID-19 coronavirus vaccine.
According to CEPI, $2 billion is needed to progress coronavirus vaccines through development as quickly as possible, leading the organisation to call for donations.
A Phase I clinical trial to investigate mRNA-1273, a vaccine to prevent the spread of the coronavirus COVID-19, has begun in the US.
The European Medicines Agency (EMA) announced it will provide free advice to those working on COVID-19 therapeutics and vaccines in the hopes of accelerating approval of a treatment.
Using AAV-based technology to deliver mAbs in a Phase I trial, researchers report that participants successfully developed antibodies against HIV.
A new vaccine formulation has been created by researchers, which uses a peelable film during drying to preserve the medicine.
Researchers have developed a solid ‘cryogel’ vaccine that has been successful in combatting acute myeloid leukaemia in mice. How was this new formulation discovered and what potential does it have for cancer patients?
European Pharmaceutical Review rounds up the latest news surrounding COVID-19, including a vaccine moving to clinical trials and the FDA's update on Chinese import inspections.
European Pharmaceutical Review explores how plants can be used for large-scale, glycosylated protein bioproduction for the pharma industry.
Researchers have developed a new formulation for cancer vaccines that could provide a solution to its delivery complications.
7 February 2020 | By OSIsoft
Trustworthiness in data is critical for operations within the pharmaceutical and life sciences industries, whether it is for compliance, operational excellence, reporting or development. Hear the latest findings from OSIsoft’s research in our on-demand webinar.
